Rapport Therapeutics (RAPP) CEO sells 8,220 shares under Rule 10b5-1 plans
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay reported open-market sales of common stock under pre-arranged Rule 10b5-1 trading plans adopted on March 27, 2026. He sold 8,220 shares on June 29, 2026 in two transactions at weighted average prices of $39.77 and $40.34 per share.
Following these sales, Ceesay held 548,027 shares of common stock directly. Additional shares are held indirectly by The Ceesay Family Irrevocable Trust and The Dorothy Ceesay Irrevocable Trust, for which he disclaims beneficial ownership except to any pecuniary interest.
Positive
- None.
Negative
- None.
Insights
CEO’s small, pre-planned stock sales look routine in scale and structure.
Rapport Therapeutics’ CEO Abraham Ceesay sold 8,220 shares of common stock on June 29, 2026, via open-market transactions under Rule 10b5-1 trading plans adopted on March 27, 2026. These plans are pre-arranged and help separate trading timing from day-to-day management decisions.
After the sales, he still directly held 548,027 shares, so the disposals represent a small fraction of his reported direct position. Additional shares are held in family trusts, where he disclaims beneficial ownership under Section 16 except for any pecuniary interest. Overall, the filing reflects routine liquidity rather than a major change in exposure.
Insider Trade Summary 10b5-1
Net Seller: 8,220 shares ($327,398)
Net Sell
4 txns
Insider
Ceesay Abraham
Role
Chief Executive Officer
Sold
8,220 shs ($327K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 7,344 | $39.7688 | $292K |
| Sale | Common Stock | 876 | $40.3375 | $35K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 548,903 shares (Direct, null);
Common Stock — 81,729 shares (Indirect, By Ceesay Family Irrevocable Trust)
Footnotes (1)
- These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.25 to $40.225, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.26 to $40.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Key Figures
Shares sold: 8,220 shares
Weighted avg price block 1: $39.7688 per share
Weighted avg price block 2: $40.3375 per share
+4 more
7 metrics
Shares sold
8,220 shares
Open-market sales on June 29, 2026
Weighted avg price block 1
$39.7688 per share
Sale of 7,344 shares of common stock
Weighted avg price block 2
$40.3375 per share
Sale of 876 shares of common stock
Direct holdings after sale
548,027 shares
Common stock held directly after June 29, 2026 trades
Dorothy Ceesay Trust holdings
20,729 shares
Common stock held indirectly by Dorothy Ceesay Irrevocable Trust
Ceesay Family Trust holdings
81,729 shares
Common stock held indirectly by Ceesay Family Irrevocable Trust
Net insider direction
Net sale of 8,220 shares
Form 4 transaction summary for June 29, 2026
Key Terms
Rule 10b5-1 trading plans, weighted average price, beneficial ownership, Section 16 of the Securities Exchange Act of 1934, +1 more
5 terms
Rule 10b5-1 trading plans regulatory
"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."
Rule 10b5-1 trading plans are written, pre-arranged instructions that allow company insiders (such as executives or directors) to automatically buy or sell their company's stock at specified times or under set conditions, like a standing instruction or automated thermostat for trades. They matter to investors because these plans provide a legal defense against insider‑trading accusations and create predictable insider trading patterns that can help signal whether sales are routine portfolio management or potentially meaningful to the company’s outlook.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 of the Securities Exchange Act of 1934 regulatory
"for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any."
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
pecuniary interest financial
"except to the extent of his pecuniary interest therein, if any."
FAQ
What insider transaction did Rapport Therapeutics (RAPP) report for CEO Abraham Ceesay?
Rapport Therapeutics reported that CEO Abraham Ceesay sold common stock in open-market transactions. On June 29, 2026, he disposed of 8,220 shares under pre-arranged Rule 10b5-1 trading plans adopted on March 27, 2026, according to the Form 4 filing.
Were the Rapport Therapeutics (RAPP) CEO’s stock sales made under a Rule 10b5-1 plan?
Yes. The Form 4 states the CEO’s transactions were effected pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. Such plans pre-schedule trades, helping insiders diversify or obtain liquidity while reducing concerns about trading on nonpublic information.
What is the role of the family trusts in the Rapport Therapeutics (RAPP) Form 4 filing?
The filing lists common shares held by The Ceesay Family Irrevocable Trust and The Dorothy Ceesay Irrevocable Trust. It notes that Abraham Ceesay disclaims beneficial ownership of these trust-held shares for Section 16 purposes, except to the extent of any pecuniary interest he may have.
Does the Rapport Therapeutics (RAPP) Form 4 indicate gifts or derivative exercises by the CEO?
No. The summarized Form 4 shows open-market sales of common stock and holding entries for indirect trust positions. It reports no derivative security exercises, gifts, tax-withholding dispositions, or restructuring transactions in this particular filing, based on the transaction summary provided.